Sign In

Chris Nolet

Independent Board Member, Former West Region Life Sciences Industry Leader & Partner at EY

Professional Background

Chris W. Nolet is a highly accomplished executive in the life sciences field with over 40 years of rich and diverse experience that reflects his steadfast commitment to advancing healthcare through innovative practices. Currently, he serves as a member of the Board of Directors for three distinguished public life science companies: Jasper Therapeutics, Revance Therapeutics, and PolarityTE. His extensive career includes holding prominent leadership roles within notable venture capital-backed companies and Fortune 100 firms, demonstrating a profound influence in the life sciences industry.

Throughout his dynamic career, Chris has not only focused on steering companies towards success but has also played an integral role in advocating for legislative changes within the pharmaceutical landscape. He has notably testified before Congress alongside Dr. Janet Woodcock from the FDA's Center for Drug Evaluation and Research (CDER), highlighting the pressing need for reforms in the FDA's regulatory framework.

In addition to these roles, Chris's former positions include the esteemed leader of the EY Life Sciences Industry Group in the western United States. His contributions to this sector have significantly shaped policies and strategies that are crucial for the development and commercialization of life sciences innovations. He currently holds a dual role on the Executive Committee and as Co-Chair of the Finance Committee for the California Life Sciences (CLS) organization, a prominent entity in fostering life sciences growth in California and beyond.

Chris's portfolio also includes past board positions with Viela Bio and Ambrx Biopharma, as well as significant involvement in financial governance through the Finance & Investment Committee and Emerging Companies Section of the Biotechnology Innovation Organization (BIO). His wealth of knowledge and insights into capital structuring, initial public offerings (IPOs), and strategic partnerships has made him a sought-after expert in the industry.

Education and Achievements

Chris's educational journey began at Saratoga High School, where he laid the foundational principles of discipline and achievement. He later advanced his studies at San Diego State University, a period that helped shape his understanding of business and finance, which has been vital throughout his professional journey.

His career at Ernst & Young (EY) began in 2001, where he made a significant impact as an elected representative on the EY Americas Advisory Council. His role encompassed both governance and advisory capacities, providing critical direction to the America’s Executive Board regarding strategic decisions and company policies.

Prior to EY, Chris was a partner at Price Waterhouse (PwC), where he was instrumental in developing the company's life sciences practice in the western United States. His ingenuity led to the approval of funding and resources necessary to establish this new branch, and he was appointed as its leader. His trailblazing spirit played a pivotal role in shaping the life sciences landscape across the region, showcasing a blend of entrepreneurial vision and executive leadership that has been a hallmark of his career.

Chris retired from EY in June 2019, having left behind a legacy of innovation and excellence. Even in retirement, he continues to be an influential figure in the life sciences community, sharing his expertise and wisdom with organizations that align with his vision for a healthier future.

Achievements

Throughout his illustrious career, Chris W. Nolet has achieved numerous accolades and milestones that highlight his position as a leader in the life sciences sector. Some of his noteworthy achievements include:

  • Leadership in Initial Public Offerings: Chris has led nearly 20 life science IPOs, guiding companies through the intricacies of becoming publicly traded entities. His expertise in navigating the IPO process has rendered him an authoritative figure in this domain.
  • National Speaking Engagements: As a featured speaker at the annual Davis Polk IPO conference, Chris has shared his insights and knowledge on the IPO landscape, further establishing his reputation as a thought leader within the industry.
  • Global Leadership with EY: As a member of the Global EY Life Sciences Executive Leadership Group until June 2019, he played a significant role in influencing policies and operational strategies for EY’s global life sciences practice, which contributes over $2 billion annually.
  • Advisory Experience: His advisory roles extend beyond EY, showcasing his potential to impact significant policy frameworks within vital organizations such as BIO. His commitment to supporting emerging companies reflects his dedication to nurturing innovation in the life sciences arena.

Chris W. Nolet’s extensive career in life sciences, coupled with his strategic vision, industry knowledge, and leadership capabilities, uniquely positions him as a pillar in the biotechnology community. His passion for fostering advancements in health care continues to make a lasting impact on the industry and the companies he passionately supporters.

Related Questions

How did Chris W. Nolet develop his expertise in life sciences and IPOs?
What motivated Chris W. Nolet to testify before Congress regarding FDA reform?
What impact has Chris W. Nolet had on the California Life Sciences organization during his tenure?
How has Chris W. Nolet contributed to advancements in healthcare through his leadership roles?
In what ways has Chris W. Nolet's experience at Ernst & Young shaped his career in life sciences?
Chris Nolet
Add to my network

Location

Incline Village, Nevada, United States